Table 1 Data describing the main cardiotoxic events reported in clinical trials of tumor angiogenesis inhibitors

Ranpura V et al. [[6]] Meta-analysis of 20 RCTs

Bevacizumab in pts with a variety of advanced solid tumors

1853

61 (3.3 %)

ATE (all-grade)

5558

111 (2.0 %)

ATE (high-grade)

2322

34 (1.5 %)

Cardiac ischemia

Richards CJ et al. [[7]]

Sunitinib

6936

186 (4.1 %)

Congestive heart failure

Choueiri TK et al. [[8]] Meta-analysis of 10 studies

Sunitinb and Sorafenib in pts with advanced cancer

9837

122 (1.4 %) 1.3 % for Sunitinib; 1.7 % for Sorafenib (NS)

ATE

Chu TF et al. [[15]]

Sunitinib in pts affected by GIST

75 36 75

8 (11 %) 6 (8 %) 10 (28 %) 7 (19 %) 35 (47 %)

Cardiovascular events Congestive heart failure LVEF reduction (at least 10 %) LVEF reduction (15 % or more) Hypertension

Telli ML et al. [[16]]

Sunitinib in pts affected by mRCC and GIST

48

7 (15 %)

Heart failure

Di Lorenzo G et al. [[17]]

Sunitinib in pts affected by mRCC

175

66 (37.7 %) 17 (9.7 %) 12 (6.9 %) 33 (18.9 %) of which 12 (6.9 %)

Hypertension G1-2 Hypertension G3 LVEF dysfunction Cardiac abnormalities LVEF G3 and/or Congestive heart failure

Schmidinger M et al. [[18]]

Sunitinib (Su) and Sorafenib (So) in pts with mRCC

74

25 [11 in Su; 14 in So] (33.8 %) of which: 12 (16.2 %) 13 (17.6 %) of which 7 (9.4 %)

Cardiac event Biochemical signs and ECG changes only Clinical symptoms (angina, dyspnea, dizziness) Life-threatening clinical symptoms